Sun Pharma announces a transformative acquisition of Organon to create a global pharmaceutical leader with significant scale.
The deal adds Women's Health and Biosimilars as new growth platforms and provides a scaled commercial footprint in 150+ markets.
Combined entity projects over $350 million in synergies and nearly doubles EBITDA and cash flows, with closing targeted for early 2027.
Transaction is subject to Organon shareholder approval and customary regulatory clearances across multiple jurisdictions.